| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,574 |
2,389 |
$173K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,957 |
1,795 |
$89K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,120 |
1,082 |
$87K |
| 99000 |
|
1,900 |
1,740 |
$42K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,186 |
1,061 |
$41K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
857 |
817 |
$40K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,287 |
1,028 |
$33K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,125 |
997 |
$17K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
154 |
114 |
$8K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
169 |
118 |
$7K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
78 |
58 |
$6K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
158 |
134 |
$5K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
438 |
372 |
$5K |
| 87428 |
|
57 |
54 |
$4K |
| 87210 |
|
463 |
446 |
$2K |
| 81002 |
|
549 |
517 |
$1K |
| 87807 |
|
81 |
77 |
$796.02 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
178 |
153 |
$384.55 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
58 |
54 |
$285.20 |
| 81025 |
|
51 |
49 |
$242.99 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
59 |
57 |
$58.47 |
| 36415 |
Collection of venous blood by venipuncture |
68 |
63 |
$6.18 |